Brentuximad Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma

Description:

For complete study information, please view the study on clincaltrials.gov.

Full IRB Study Title:
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

IRB Study ID:
1038558-1

If you are interested in this study or have questions about your child's eligibility, please contact: Rebecca D. Considine Research Institute, 330-543-5012


Lead Principal Investigator:

Photo
Steven Kuerbitz, MD
Director, Divisional Research and Stem Cell Transplantation


Bookmark and Share

Developments Developments
Sign up for enewsletter
Get involved Get involved
Discover ways to support Akron Children's
    Contact Us

    330-543-5012

    E-mail

    find a location
    Find a location Type the first 3-5 letters of a specialty, service or location:
    Or, view: a map, a list of all locations, locations by city or locations near me.
    find a doctor
    Find a doctor Type the first 3-5 letters of the name, location or specialty:
    Or, view a list of all doctors by name, location and specialty.